Fig. 8From: Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trialsForest plot of meta-analysis for the comparison of adverse endocrine events between the SGLT-2i and placebo groups. a Hypoglycaemia adverse outcomes, b diabetic ketoacidosis adverse outcomesBack to article page